ERBB2 and gastric cancer: In a phase II study of third-line treatment for locally advanced or metastatic Her-2 overexpressing gastric cancer or gastroesophageal junction cancer (22), the results showed an ORR of 24.4%, a median PFS of 4.1 months, and a median OS of 7.6 months.